Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lexaria Bioscience ( (LEXX) ) has shared an announcement.
Lexaria Bioscience Corp. has begun dosing in its pioneering study examining the biodistribution of DehydraTECH-semaglutide molecules in rodents. The study aims to determine if DehydraTECH can improve the biodistribution of semaglutide compared to conventional methods, potentially enhancing its efficacy and reducing side effects. Results could bolster Lexaria’s communications with industry partners and impact its position in the drug delivery market.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing drug efficacy through its proprietary DehydraTECH technology.
YTD Price Performance: -19.13%
Average Trading Volume: 192,008
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $32.65M
See more data about LEXX stock on TipRanks’ Stock Analysis page.
